The Politics of Lyme Disease: Why Patients Are Caught in the Middle
Lyme disease politics continue to shape how patients are diagnosed, treated, and ultimately understood. When competing medical viewpoints influence care, patients may be caught in the middle.
Lyme in the Limelight, published by Hamodia, features interviews with leading voices in Lyme disease research, clinical care, and advocacy.
The series highlights a fundamental divide between two perspectives:
- The Infectious Diseases Society of America (IDSA)
- The International Lyme and Associated Diseases Society (ILADS)
Below are excerpts illustrating this ongoing debate.
IDSA Perspective
Dr. Eugene Shapiro, Infectious Diseases Society of America (IDSA)
“Lyme disease is not difficult to diagnose and it’s a well-defined entity. It’s generally relatively easy to treat.”
“To be clear, I believe that these patients suffer symptoms, but it’s not causally related to Lyme.”
Dr. Shapiro also questioned higher estimates of Lyme disease prevalence, suggesting that increases are limited and not indicative of a broader epidemic.
“There is no such thing as chronic Lyme disease.”
ILADS Perspective
Dr. Daniel Cameron, International Lyme and Associated Diseases Society (ILADS)
“The Lyme disease patient’s quality of life is the same or worse than conditions such as diabetes, myocardial infarction, fibromyalgia, and chronic fatigue.”
“ILADS recommends prophylactic treatment for at least three weeks with follow-up after a tick bite.”
ILADS emphasizes that treatment decisions should consider long-term outcomes, not just short-term symptom resolution.
“There are doctors who dismiss Lyme disease, leading to needless treatment delays.”
The Consequences of This Divide
This disagreement is not merely academic—it has real consequences for patients.
When Lyme disease is dismissed or narrowly defined:
- Diagnosis may be delayed
- Treatment may be limited
- Patients may be told their symptoms are unrelated
These outcomes can lead to prolonged illness and significant reductions in quality of life.
Why This Matters
When political and institutional forces—rather than patient need—determine care, the impact extends beyond clinical outcomes.
It becomes an ethical issue.
I examine these systemic challenges in greater detail in the ethics of Lyme disease diagnosis and treatment.
(Reprinted with permission from Hamodia. For more information, visit hamodia.com.)
To read the full two-part series, download below:
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
All I can say is thanks to Dr. Daniel Cameron and all the other Dr. Cameron out there who have stayed true to your oath as a doctor and persisted regardless of the peer pressure and legal pressure to turn away from the patients afflicted with tick borne illness!!! Also, I strongly hope that Dr. Shapiro is called out one day for his comments in this article and is made accountable. Sometimes words speak louder than actions and his case he has done it again and again. Time to come of the pedestal you put yourself on and admit – maybe just maybe I made a very big error!!!
Thank you Dr. Cameron for all you do. As for Mr. Shapiro. One day he will be counting up all those undiagnosed patients that died and MS and Alzheimer’s patients that could have been helped better with a better test and correct knowledge in the field of Lyme disease. It is my true gut feeling that Mr. Shapiro is more of a corporate man that patients caretaker. Unfortunately I have seen many doctors through the years chasing one diagnosis after the other. You get a good feel for the ones who wanted to be a Doctor for their patients and the ones who0 are in it for the big house and nice cars.